1584647-27-7 ((Bms-986115)

Notch inhibitor 1;BMS 986115;LSK1L593UU;(2R,3S)-N1-[(3S)-5-(3-Fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide;DB13126;SB16946;US9273014, 1;Q27283163;(2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide;(2R,3S)-N1-((S)-5-(3-Fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-b;Bms-986115;(2R,3S)-N-[(3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide;NSC-836050;AL 102;Varegacestat;SRJNRAQUSAVENA-GSHUGGBRSA-N;MS-30346;P14960;DA-51257;CS-0012731;BMS 986115 [WHO-DD];1584647-27-7;NS00073619;Butanediamide,N1-[(3S)-5-(3-fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)-,(2R,3S)-;AKOS027337116;(2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)butanediamide;AL-102;UNII-LSK1L593UU;CHEMBL3911164;(2R,3S)-N1-[(3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide;SCHEMBL15608290;BMS986115;(2S,3R)-N'-[(3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide;Butanediamide, N1-[(3S)-5-(3-fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)-, (2R,3S)-;varegacestat [INN];GS/pan-Notch Inhibitor AL102;NSC836050;HY-12860;Butanediamide, N1-((3S)-5-(3-fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)-, (2R,3S)-;

SRJNRAQUSAVENA-GSHUGGBRSA-N

1S/C26H25F7N4O3/c1-13-4-2-7-18-19(13)36-24(40)22(35-20(18)14-5-3-6-15(27)12-14)37-23(39)17(9-11-26(31,32)33)16(21(34)38)8-10-25(28,29)30/h2-7,12,16-17,22H,8-11H2,1H3,(H2,34,38)(H,36,40)(H,37,39)/t16-,17+,22+/m0/s1

FC(CC[C@@H](C(N[C@@H]1C(NC2C(C)=CC=CC=2C(C2C=CC=C(C=2)F)=N1)=O)=O)[C@@H](C(N)=O)CCC(F)(F)F)(F)F